Testing a new lung cancer medication in European patients

Plain-English translation of NCT07130916 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called in people with advanced lung cancer that has specific genetic changes (EGFR mutations). The study will look at how the medication moves through your body, whether it is safe to take, and how well you tolerate it. You would take this treatment as a daily oral tablet.

Lung cancer with EGFR mutations can be hard to treat, especially after other therapies stop working. This medication is designed to target these specific mutations, and researchers need to understand how it works in European patients and confirm it is safe and tolerable.

Do you qualify?

You likely qualify if…

you are at least 18 years old and of European descent or citizenship
you have been diagnosed with advanced or recurring non-small cell lung cancer that cannot be treated with surgery or radiation alone
your lung cancer has been confirmed to have at least one EGFR mutation (ex19del, L858R, or T790M)
you have a good overall health status and life expectancy of at least 12 weeks
your blood counts and organ function are adequate (measured by blood tests)

You likely don't qualify if…

you have small cell lung cancer or mixed small and non-small cell elements
you have received multiple lines of prior EGFR-targeting therapies (with some limited exceptions)
your blood counts or organ function tests are too low or abnormal
you are pregnant or nursing

What participation looks like

You would take a daily tablet of the medication by mouth for 21-day cycles. During the first cycle, you would visit the study site several times (Days 1, 2, 8, and 15) for blood draws to measure how the medication moves through your body. After the first two cycles, if the treatment is working and you tolerate it well, you can continue taking it at home with less frequent clinic visits and tumor scans. The study lasts until your cancer progresses, intolerable side effects occur, or your doctor decides to stop treatment.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(6 sites)

Bosnia and Herzegovina

Republika Srpska University Clinical Centre of the Republic of Srpska, Dvanaest beba bb, Banja Luka

University Clinical Hospital Mosta, Bijeli Brijeg bb, Mostar

Clinical Center University of Sarajevo, Bolnicka 25, Sarajevo

Cantonal Hospital Zenica, Crkvice 67, Zenica

Bulgaria

MHAT "Sveta Sofia" Departmet of Medical Oncology Bulgaria Blvd, Sofia, Grad